{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-26-000049","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2026-08-05T20:14:24+00:00","discovered_at":"2026-08-05T20:15:00.269746+00:00","generated_at":"2026-08-05T20:15:12.041739+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns","bullets":["Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.","Raised FY2026 net product sales guidance to $525M-$540M from $480M-$495M.","FDA approved ZORYVE cream 0.3% for children aged 2+; sNDA accepted for ZORYVE cream 0.05% in infants (PDUFA Feb 23, 2027).","CCO L. Todd Edwards resigns effective Aug 21; Robert Lisicki appointed interim CCO (base $555K, equity grants).","Positive operating cash flow $12.6M; cash $238.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-26-000049","json":"https://secwatch.observer/filing/0001787306-26-000049.json","markdown":"https://secwatch.observer/filing/0001787306-26-000049.md","text":"https://secwatch.observer/filing/0001787306-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/arqt-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:15:12.041739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9af3196c39","claim":"Robert Lisicki was appointed as interim chief commercial officer at Arcutis Biotherapeutics, Inc..","evidence_excerpt":"has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim chief commercial officer"}],"fact_type":"executive_change"},{"claim_id":"dc96669ca1","claim":"L. Todd Edwards resigned as chief commercial officer at Arcutis Biotherapeutics, Inc..","evidence_excerpt":"On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"chief commercial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}